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Non-technical summary Nerve cells (neurones) in the body communicate with each other by
releasing chemicals (neurotransmitters) which act on proteins called receptors. An important
group of receptors (called G protein coupled receptors, GPCRs) regulate the release of neuro-
transmitters by an action on the ion channels that let calcium into the cell. Here, we show for
the first time that small peptides based on specific regions of calcium ion channels involved in
GPCR signalling can themselves inhibit nerve cell communication. We show that these peptides
act directly on calcium channels to make them more difficult to open and thus reduce calcium
influx into native neurones. These peptides also reduce GPCR-mediated signalling. This work is
important in increasing our knowledge about modulation of the calcium ion channel protein;
such knowledge may help in the development of drugs to prevent signalling in pathways such as
those involved in pain perception.
Abstract Modulation of presynaptic voltage-dependent Ca2+ channels is a major means of
controllingneurotransmitter release. TheCaV2.2Ca2+ channel subunit contains several inhibitory
interaction sites for Gβγ subunits, including the amino terminal (NT) and I–II loop. The NT and
I–II loop have also been proposed to undergo a G protein-gated inhibitory interaction, whilst
the NT itself has also been proposed to suppress CaV2 channel activity. Here, we investigate the
effects of an amino terminal (CaV2.2[45–55]) ‘NT peptide’ and a I–II loop alpha interaction
domain (CaV2.2[377–393]) ‘AID peptide’ on synaptic transmission, Ca2+ channel activity and
G protein modulation in superior cervical ganglion neurones (SCGNs). Presynaptic injection
of NT or AID peptide into SCGN synapses inhibited synaptic transmission and also attenuated
noradrenaline-induced G protein modulation. In isolated SCGNs, NT and AID peptides reduced
whole-cell Ca2+ current amplitude, modified voltage dependence of Ca2+ channel activation
and attenuated noradrenaline-induced G protein modulation. Co-application of NT and AID
peptide negated inhibitory actions. Together, these data favour direct peptide interaction with
presynaptic Ca2+ channels, with effects on current amplitude and gating representing likely
mechanisms responsible for inhibition of synaptic transmission. Mutations to residues reported
as determinants of Ca2+ channel function within the NT peptide negated inhibitory effects on
synaptic transmission, Ca2+ current amplitude and gating andG proteinmodulation. Amutation
within the proposed QXXER motif for G protein modulation did not abolish inhibitory effects
of the AID peptide. This study suggests that the CaV2.2 amino terminal and I–II loop contribute
molecular determinants for Ca2+ channel function; the data favour a direct interaction of peptides
with Ca2+ channels to inhibit synaptic transmission and attenuate G protein modulation.
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Introduction
Presynaptic inhibition of neurotransmitter release is a
fundamental process at central synapses and may be
controlled via the modulation of voltage-dependent Ca2+
channel activity. The presynaptic CaV2 Ca2+ channel
family (comprising CaV2.1, CaV2.2 and CaV2.3 iso-
forms) encode themajor, pore-forming α1 subunit, which
associates with auxiliary CaVβ, α2-δ and, sometimes,
γ subunits (Ertel et al. 2000; Catterall et al. 2005). A
dominant formof feedback inhibitionofneurotransmitter
release from presynaptic terminals is mediated by the
interaction between Gβγ subunits, liberated by activation
of G protein-coupled receptors (GPCRs), and CaV2 α1
subunits (Ikeda, 1996; Herlitze et al. 1996; Kajikawa et al.
2001; Stephens & Mochida, 2005; Stephens, 2009). CaV2
α1 subunits contain distinct regions which interact with
Gβγ subunits (Dolphin, 2003; De Waard et al. 2005;
Tedford & Zamponi, 2006). Themajor interaction regions
are: (i) the amino terminal (NT) (Page et al. 1998; Stephens
et al. 1998b; Simen&Miller, 1998, 2000; Cantı´ et al. 1999);
(ii) sites on the intracellular loop connecting domains I
and II (I–II loop), the major site partially overlapping
with a CaVβ binding site and termed the alpha interaction
domain (AID) (De Waard et al. 1997; Herlitze et al. 1997;
Zamponi et al. 1997); and (iii) the carboxyl terminal (Qin
et al. 1997; Li et al. 2004). Overall, the carboxyl terminal
is suggested to play only a minor role (Stephens et al.
1998b; Agler et al. 2005), but may act to increase Gβγ
affinity for the channel (Li et al. 2004). In addition to
these studies, Agler et al. (2005) have proposed a physical
interaction between the NT and the I–II loop to form a G
protein-gated inhibitorymodule and cause a ‘constitutive’
suppression of Ca2+ current. The co-expression of the NT
domain has also been shown to cause a dominant-negative
suppression of CaV2 channels (Raghib et al. 2001; Page
et al. 2004, 2010).
The studies described above have been performed in
recombinant cells and the situation in native neuro-
nes is less clear. Moreover, despite the identification
and extensive molecular mapping of Ca2+ channel/Gβγ
interaction sites, the relative functional contributions
of different CaV2 sites to presynaptic inhibition of
neurotransmitter release remain unknown. Superior
cervical ganglion (SCG) neurones (SCGNs) expressing
CaV2.2 channels represent a well-characterized system for
investigating synaptic transmission and Gβγ modulation
(Ikeda, 1991, 1996; Stephens&Mochida, 2005).Therefore,
we examined the effects of synthetic CaV2.2 peptides based
on the NT and AID region in SCGNs. We demonstrate,
for the first time, that CaV2.2 peptides can act directly
to inhibit synaptic transmission; we present evidence that
peptide mechanism of action involves a reduction in Ca2+
current amplitude and also a modification of activation
gating properties. These effects are accompanied by an
attenuation of G protein modulation. Together, these
data may explain previous findings for peptides based
on the AID and NT regions. We also use mutagenesis
to identify CaV2.2 NT residues important for inhibitory
effects, suggesting that the NT is a crucial determinant of
Ca2+ channel function, including inhibition of transmitter
release and G protein modulation.
Methods
Tissue culture
SCGNs for microelectrode recording. Cells were prepared
as previously described (Mochida et al. 1994). Briefly,
Wistar rats were decapitated on postnatal day 7 under
diethylether anaesthesia according to the guidelines of the
Physiological Society of Japan. SCGNs were isolated and
maintained in culture for 6–7 weeks in a growth medium
of 84% Eagle’s minimal essential medium, 10% fetal calf
serum, 5% horse serum, 1% penicillin–streptomycin (all
Gibco Invitrogen Corporation, NY, USA) and 25 ngml−1
nerve growth factor (2.5 S, grade II; Alomone, Jerusalem,
Israel).
SCGNs for patch clamp recordings. Neurones were
acutely dissociated from the SCG of 3- to 6-week-old
Wistar rats according to the guidance of the UK
Animals (Scientific Procedures) Act 1986. Animals were
anaesthetized with isoflurane (BDH, Loughborough, UK)
and decapitated. Ganglia were dissociated and transferred
to L-15 medium (Sigma Aldrich, Poole, UK) containing
5% penicillin–streptomycin (Gibco Invitrogen, Paisley,
UK). After centrifugation at 800 r.p.m. (= 72 g) for 2 min
at room temperature, L-15 medium was replaced by an
enzymatic solution of 0.5 mgml−1 trypsin, 1 mgml−1
collagenase with 3.6 mgml−1 glucose (all Sigma Aldrich).
Ganglia were maintained in the enzymatic solution for
30–40min at 37◦C and dissociated by gentle trituration
every 10min with fire-polished Pasteur pipettes.
Enzymatic digestion was arrested by addition of growth
medium comprising: 84% Eagle’s minimal essential
medium, 10% fetal calf serum, 5% horse serum (all
Lonza,Wokingham, UK) and 1% penicillin–streptomycin
(Gibco Invitrogen). After centrifugation at 800 r.p.m.
(= 72 g) for 4 min at room temperature (20–22◦C),
pellets were re-suspended in growth medium and
plated onto coverslips coated with poly-L-ornithine
(Sigma Aldrich) and incubated overnight at
37◦C (5%CO2) prior to electrophysiological recordings.
Electrophysiology
Synaptic transmission between SCGNs. Conventional
paired intracellular recordings were made from two
proximal neurones using microelectrodes filled with 1 M
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potassium acetate (70–90M) as described previously
(Mochida et al. 2003). Briefly, SCGNs were superfused
with modified Krebs solution containing (in mM): NaCl
136, KCl 5.9, CaCl2 2.5, MgCl2 1.2, glucose 11, Na-Hepes,
3; pH 7.4 (adjusted with NaOH). Action potentials
were generated in a neurone by current injection (at
0.1 Hz) through the intracellular recording electrode and
excitatory postsynaptic potentials (EPSPs) recorded from
the other neurone. Peptides were dissolved to a final
concentration of 1 mM in a solution containing (in mM):
potassium acetate 150, Mg-ATP 5, Hepes 10; pH 7.3, and
introduced for 3–4min into the cell body of SCGNs froma
glass pipette (16–18M) alongwith fast greenFCS (Sigma
Aldrich) to visualize successful injection (Mochida et al.
1996). Data were analysed using software written by the
late Ladislav Tauc (CNRS, France). Statistical significance
was determined using Student’s t test.
Whole-cell patch clamp recordings. Whole-cell recording
from isolated SCGNs was performed as previously
described (Stephens & Mochida, 2005) using an intra-
cellular solution containing (in mM): CsCl 140, Hepes
10, CaCl2 0.1, MgCl2 1.0, Mg-ATP 4, EGTA 1.0;
pH 7.3 (adjusted with CsOH) and an extracellular
solution containing (in mM): TEA-Br 160, Hepes 10,
KCl 3, MgCl2 1, glucose 4, NaHCO3 1.0 with 10mM
Ba2+ as charge carrier; pH 7.4 (adjusted with Sigma
7–9 base). Data were obtained at room temperature.
Membrane currents were acquired with an Axopatch 200B
patch-clamp amplifier. Linear components of capacitive
and leak currents were subtracted using the standard
P/4 protocol. Series resistance compensation of >70%
was typically employed. For GPCR-mediated inhibition
studies, noradrenaline (10μM final concentration) was
bath-applied. NT, AID or mutated peptides were freshly
dissolved in intracellular solution to a final concentration
of 1 mM in the patch electrode immediately prior to
use. Data were analysed offline using WinWCP v4.0.7
(John Dempster, University of Strathclyde), OriginPro
7.0 (Microcal, Northampton, MA, USA) and MATLAB
(The MathWorks, Natick, MA, USA) software. Values
reported are means± SEM. Statistical significance was
determined using Mann–Whitney U tests or Student’s
t test as appropriate.
Pharmacology. The following agents were used:
ω-conotoxin GVIA (Alomone Labs, Jerusalem, Israel),
noradrenaline (Sigma Aldrich), pertussis toxin (PTX)
(Tocris Cookson, Bristol, UK). Synthetic peptides were
purchased from Peptide Specialty Laboratories GmbH
(Heidelberg, Germany) and had the following sequences:
NT peptide (rat CaV2.2[45–55]), YKQSIAQRART;
mutant NT peptide, YKQSIAQAAAT; AID peptide (rat
CaV2.2[377–393]), RQQQIERELNGYLEWIF; mutant
AID peptide, RQQQLERELNGYLEWIF.
The authors have read, and the experiments comply
with, the policies and regulations of The Journal of Physio-
logy described by Drummond (2009).
Results
Effects of AID and NT peptides on synaptic
transmission and G protein modulation
In model SCGN synapses. We first investigated the
effects of presynaptic injection of an amino terminal
(CaV2.2[45–55]) ‘NT peptide’ and a I–II loop alpha
interaction domain (CaV2.2[377–393]) ‘AID peptide’ in
long-term SCGN cultures, an appropriate model for
the study of fast synaptic transmission and modulation
of Ca2+ channels (Stephens & Mochida, 2005; Ma &
Mochida, 2007); for all experiments in model SCGN
synapses, CaV2.2 peptides were injected into the pre-
synaptic cell at 1 mM. Presynaptic injection of the NT
peptide caused a significant decrease in EPSP amplitude
recorded in synaptically coupled cells (25.3± 5.5%, n= 6,
P < 0.05; Fig. 1Aa and d). Similarly, AID peptide caused
a significant decrease in EPSP amplitude (36.5± 11.0%,
n= 6, P < 0.05; Fig. 1Ab and d). A scrambled 17mer
AID peptide had no significant effect on EPSP amplitude
(4.6± 4.2%, n= 8, P > 0.05; Fig. 1Ac and d). These data
are consistent with synthetic CaV2.2 peptides causing
direct inhibition of cholinergic transmission in model
SCGN synapses.We next investigated the effects of the NT
and AID peptide on G protein modulation. Consistent
with our previous studies (Stephens & Mochida, 2005),
the GPCR agonist noradrenaline (NA; 10μM) caused a
clear reduction in EPSP amplitude (40.4± 6.8%, n= 5;
Fig. 1Ba and d). This NA-induced decrease in EPSP
amplitude was significantly reduced in the presence of
1 mM NT peptide (20.8± 6.2%, n= 5, P < 0.05; Fig. 1Bb
and d) and virtually abolished in the presence of 1 mM
AID peptide (1.0± 6.1%, n= 5, P < 0.05; Fig. 1Bc and
d). Here, NA effects were normalized to inhibition caused
by pre-injection of the NT or AID peptide; therefore,
residual NA effects in the presence of the NT peptide
most likely reflect differences in magnitude of inhibition
between AID and NT peptides (see Fig. 1Ad). These data
demonstrate that CaV2.2 NT and AID peptides inhibit
synaptic transmission in SCGN synapses and that these
actions are accompanied by an attenuation of G protein
modulation. It has been reported that similar AID-based
peptides (Herlitze et al. 1997; Zamponi et al. 1997) and a
peptide based on the entire NT[1–95] domain (Agler et al.
2005) attenuate G protein modulation in recombinant
cells; however, it has beenunclear if peptides simply chelate
free Gβγ (Zamponi et al. 1997) or, alternatively, bind the
channel itself and the resultant complex is now insensitive
C© 2011 The Authors. Journal compilation C© 2011 The Physiological Society
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to G protein modulation (Agler et al. 2005). Our data on
synaptic transmission initially favour the latter scenario,
as Gβγ chelation would be expected to remove G protein
inhibition and increase synaptic transmission.
Effects of AID and NT peptides on Ca2+ channels
and G protein modulation in isolated SCGNs
In order to explore potential mechanisms of peptide
action, we examined the effects of the NT and AID
peptide on whole-cell Ca2+ current (measured as IBa)
in isolated SCGNs as the best available model of the
heterogeneous Ca2+ channel population most likely pre-
sent at the presynapse; for all experiments in isolated
SCGNs, CaV2.2 peptides were included in the intra-
cellular solution at 1 mM. We first noted that NT and
AID peptides had effects on the voltage dependence of
Ca2+ channel activation. In control cells, activation curves
were seen to display symmetry about their midpoint
and, therefore, were best fitted by a single Boltzmann
distribution (96± 1%, n= 10; Fig. 2Aa, Table 1). By
contrast, in the presence of either CaV2.2 peptide,
activation curves could be well described only by the
sum of two Boltzmann distributions. Thus, a lower, more
hyperpolarized first component of midpoint of voltage
dependence of activation V 0.5(1) component (NT peptide:
62± 3%, n= 11; AID peptide: 56± 3%, n= 8) and a
higher, more depolarized second component of midpoint
of voltagedependenceof activationV 0.5(2) component (NT
peptide: 38± 3%, n= 11; AID peptide: 44± 3%, n= 8)
were required to best fit the data (Fig. 2Ab and c, Table 1).
The second component was also associated with a shallow
slope factor (Table 1).
We have previously demonstrated that NA inhibits
synaptic transmission in SCGNs via Gβγ-mediated
inhibition of IBa (Stephens&Mochida, 2005). NA (10μM)
significantly reduced IBa by 55.4± 4.8%, n= 11 (P < 0.05
vs. pre-drug IBa) (Fig. 2Ba and d). NA inhibition of Ca2+
current was accompanied by a significant, characteristic
depolarizing shift inV 0.5 of∼+12mV (Fig. 2Ca, Table 1);
to best estimate this effect, fully Gβγ-modulated channels
were compared with channels following a conditioning
prepulse (PP) to +120mV to maximally relieve any
endogenous G protein modulation (Stephens et al.
1998a). Pre-incubation (20 h) with 500 ngml−1 pertussis
toxin (PTX) abolished the NA-induced shift in V 0.5
(Table 1).NA-induced inhibitionof IBa was subject to clear
prepulse facilitation (PPF), as measured by a significant
increase in facilitation ratio (P2:P1) from 1.44± 0.14 to
1.88± 0.24 at −10mV (n= 10, P < 0.05; Fig. 3Aa and
Ba). PPF also reversed the NA-induced shift in V 0.5 (to
2.8± 3.1 mV, n= 10, P < 0.05; Fig. 3Ca, Table 1). Effects
of prepulses on NA-mediated inhibition of IBa were also
preventedbyPTXpre-treatment, as evidencedbyabolition
of the NA-induced shift in V 0.5 (Table 1). Together,
these data confirm a robust GPCR-mediated inhibition
of Ca2+ channels and the isolation of appropriate
voltage-dependent pathways to study CaV2.2 peptide
effects in native SCGNs.
We next investigated the effects of free cytosolic NT
or AID peptide on G protein modulation of Ca2+
channels. NA-induced inhibition of IBa was significantly
attenuated in the presence of theNT (32.4± 3.5%, n= 11,
P < 0.05; Fig. 2Bb and d) and the AID (35.6± 2.8%,
n= 10, P < 0.01; Fig. 2Bc and d) peptide. PPF of the
NA-inhibited IBa was significantly reduced in the pre-
sence of the NT (P2:P1: 1.21± 0.03, n= 11; Fig. 3Ab
and Bb) and the AID (P2:P1: 1.09± 0.05, n= 8; Fig. 3Ac
and Bc) peptide (measured at −10mV, both P < 0.01 vs.
control facilitation ratio shown in Fig. 3Ba). Whilst large
depolarizing prepulses readily reversed the NA-induced
shift in V 0.5 in control conditions (Fig. 3Ca, Table 1),
no PPF was evident in the presence of either the
NT (Fig. 3Cb, Table 1) or the AID (Fig. 3Cc, Table 1)
peptide. These data demonstrate that CaV2.2 peptides
had inhibitory effects on voltage-dependent pathways
under these conditions. In the absence of NA-mediated
inhibition, a small amount of basal PPFwas seen in control
conditions (Fig. 3Ba). This basal PPF was also seen in the
presence of the NT (P2:P1: 1.23± 0.03, n= 11; Fig. 3Bb)
and the AID (P2:P1: 1.24± 0.05, n= 8; Fig. 3Bc) peptide
Figure 1. Presynaptic injection of synthetic CaV2.2 peptides inhibits synaptic transmission and
attenuates subsequent G protein modulation in SCGN synapses
A, effect of NT (1 mM) (a), AID (1 mM) (b; inset shows representative EPSP traces for effects of AID peptide, prior
to (control) and 20 min after peptide injection (AID peptide 20′)) and scrambled 17mer AID (1 mM) (c) peptides on
EPSP amplitude. Ad, bar graph summarizing effects of synthetic CaV2.2 peptides on mean EPSP amplitudes (at
20 min after peptide injection), ∗P < 0.05 vs. control EPSP amplitude prior to peptide injection or †P < 0.05 for
AID peptide (only) vs. decrease in EPSP amplitude caused by scrambled AID peptide (Student’s t test). In this figure
and Figs 4–6, EPSPs were evoked at a frequency of 0.1 Hz and were normalized to amplitude prior to peptide
injection into the presynapse at time = 0 min; continuous line shows smoothed values of the EPSP amplitudes. B,
effect of 10 μM NA on EPSP amplitude in control (a) and in the presence of NT peptide (1 mM) (b) and AID peptide
(1 mM) (c); NA was bath-applied 30 min after injection of the peptide. EPSPs were normalized to amplitude prior
to NA application at time = 0 min. Bd, bar graph summarizing NA effects, ∗P < 0.05 vs. NA effects in controls
(Student’s t test).
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Figure 2. Synthetic CaV2.2 peptides attenuate NA-induced inhibition of IBa
A, voltage dependence of activation curves from tail current amplitude data in control (a) and in the presence
of NT peptide (1 mM) (b) and AID peptide (1 mM) (c). In this and subsequent figures, tail current amplitude at
−120 mV was normalized to the maximum current and plotted against test pulse potential. Control tail current
activation curve data (Aa) were described by one Boltzmann distribution; data recorded in the presence of the NT
(Ab) and the AID (Ac) peptide were well fitted only by two Boltzmann distributions (mean ± SEM values derived
from individual cells are shown in Table 1). B, representative traces showing NA (10 μM)-induced inhibition of IBa
in control (a), and in the presence of NT peptide (1 mM) (b) and AID peptide (1 mM) (c). Bd, bar graph summarizing
percentage IBa inhibition by NA (10 μM) showing pooled data for controls (white bar), and in the presence of NT
peptide (black bar) and AID peptide (grey bar); ∗P < 0.01 vs. control (Mann–Whitney U test). In this and subsequent
figures, effects were measured at −10 mV (as G protein modulation is most pronounced at moderate depolarizing
steps, Bean, 1989); holding current = −70 mV, scale bars in Ba apply to each trace Ba–c. C, effects of 10 μM NA
on voltage dependence of activation curves from tail current amplitude data in control (a) and in the presence of
NT peptide (1 mM) (b) and AID peptide (1 mM) (c). Control tail current activation curve data (Ca) were described by
one Boltzmann distribution; data recorded in the presence of the NT (Cb) and AID (Cc) peptide ( ± NA) were well
fitted only by two Boltzmann distributions (mean ± SEM values derived from individual cells are shown in Table 1).
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Table 1. Electrophysiological characteristics of SCGN whole-cell Ca2+ current
V0.5(1) (mV) k1 (mV) V0.5(2) (mV) k2 (mV) A1 A2 n
CTL 3.6 ± 3.4 8.0 ± 0.8 — — 0.96 ± 0.01 — 10
CTL+PP −0.1 ± 3.1 6.2 ± 0.9 — — 0.96 ± 0.01 —
CTL+NA 11.9 ± 3.2∗δ 12.0 ± 0.7∗∗δδ — — 0.96 ± 0.01 —
CTL+NA+PP 2.8 ± 3.1† 8.2 ± 0.8†† — — 0.95 ± 0.01 —
NT −12.1 ± 1.8 4.0 ± 0.6 18.0 ± 5.2 16.3 ± 1.5 0.62 ± 0.03 0.38 ± 0.01 11
NT+PP −14.0 ± 1.5 3.2 ± 0.5 15.1 ± 5.6 16.7 ± 2.7 0.67 ± 0.04 0.33 ± 0.04
NT+NA −14.4 ± 1.7 3.6 ± 0.6 11.2 ± 6.2 14.5 ± 1.2 0.55 ± 0.05 0.44 ± 0.05
NT+NA+PP −15.8 ± 1.7 3.7 ± 0.7 14.9 ± 6.0 15.0 ± 1.5 0.72 ± 0.04 0.27 ± 0.04
AID −6.9 ± 2.0 3.6 ± 0.6 16.2 ± 4.0 15.6 ± 1.4 0.56 ± 0.03 0.44 ± 0.03 8
AID+PP −8.7 ± 1.9 3.6 ± 0.4 14.2 ± 5.3 12.5 ± 1.4 0.64 ± 0.05 0.38 ± 0.05
AID+NA −9.2 ± 2.1 4.6 ± 1.1 21.7 ± 6.8 14.9 ± 2.3 0.64 ± 0.07 0.36 ± 0.07
AID+NA+PP −11.8 ± 1.5 4.2 ± 0.4 23.8 ± 7.4 13.4 ± 1.8 0.65 ± 0.05 0.35 ± 0.05
Mutant AID −7.5 ± 1.9 3.6 ± 0.7 19.3 ± 3.1 16.1 ± 1.4 0.56 ± 0.04 0.45 ± 0.05 7
Mutant AID+PP −10.5 ± 1.9 3.5 ± 0.3 16.2 ± 2.1 14.7 ± 2.2 0.58 ± 0.05 0.43 ± 0.05
Mutant AID+NA −7.4 ± 3.3 5.0 ± 0.3 21.2 ± 9.1 17.1 ± 3.2 0.62 ± 0.05 0.40 ± 0.05
Mutant AID+NA+PP −7.3 ± 3.5 4.3 ± 1.0 19.4 ± 8.8 13.9 ± 3.4 0.60 ± 0.10 0.40 ± 0.10
Mutant NT −3.8 ± 3.5 8.3 ± 1.6 — — 0.96 ± 0.01 — 8
Mutant NT+PP −8.4 ± 2.9 6.6 ± 1.4 — — 0.94 ± 0.01 —
Mutant NT+NA −1.4 ± 2.6∗ 9.7 ± 0.9∗∗ — — 0.94 ± 0.01 —
Mutant NT+NA+PP −5.0 ± 3.0 8.4 ± 1.5 — — 0.95 ± 0.01 —
NT+AID −3.5 ± 1.1 9.4 ± 0.9 — — 0.97 ± 0.01 — 10
NT+AID+PP −8.7 ± 0.7 7.9 ± 0.6 — — 0.97 ± 0.01 —
NT+AID+NA 5.0 ± 1.7∗∗δ 15.3 ± 1.3∗∗δδ — — 0.96 ± 0.02 —
NT+AID+NA+PP −4.0 ± 1.3† 10.7 ± 1.2†† — — 0.94 ± 0.01 —
PTX −7.2 ± 2.2 7.9 ± 1.0 — — 0.96 ± 0.01 — 6
PTX+PP −9.0 ± 1.8 7.2 ± 1.5 — — 0.96 ± 0.01 —
PTX+NA −7.2 ± 1.8 9.0 ± 1.0 — — 0.94 ± 0.01 —
PTX+NA+PP −10.2 ± 0.9 7.7 ± 1.2 — — 0.96 ± 0.01 —
Normalized tail current amplitude data were plotted against voltage and fitted with either a single or dual Boltzmann as appropriate.
CTL, control; NA, noradrenaline (10 μM); PP, prepulse (to +120 mV). A1 = amplitude of first component of Boltzmann function; A2 =
amplitude of second component of Boltzmann function. ∗P < 0.05, ∗∗P < 0.01 vs. control + PP; †P < 0.05, ††P < 0.01 vs. control + NA;
δP < 0.05, δδP < 0.01 vs. control; Mann–Whitney U tests.
at levels not significantly different to control (measured
at −10mV, both P > 0.05). Whilst CaV2.2 dominate
somatic whole-cell Ca2+ current in SCGNs, there is a
small contribution from CaV1 channels (Jones & Jacobs,
1990). Although CaV1 channels do not contribute to
NA effects here (see Supplemental Fig. 1, available online
only) or support transmitter release (Mochida et al. 2003),
basal PPF was significantly reduced by 10μM nifedipine
(Supplemental Fig. 1), consistent with an alternative,
CaV1-mediated component of basal voltage-dependent
PPF (Lee et al. 2006) in SCGNs. The lack of difference
in basal PPF between control and CaV2.2 peptides further
suggests that peptides do not interact with CaV1 channels
here.
As seen in controls above, under conditions of
NA-induced inhibition and subsequent application of a
conditioning prepulse, Ca2+ channel activation followed
a single Boltzmann distribution in control cells (Figs 2Ca
and 3Ca; Table 1), but again was best fitted by a dual
Boltzmann distribution for the NT (Figs 2Cb and 3Cb;
Table 1) and the AID (Fig. 2Cc and 3Cc; Table 1) peptide
under both conditions. There were no significant effects
on either V 0.5(1) or V 0.5(2) components in the response
to NA in the presence of the NT (Fig. 2Cb, Table 1) and
the AID (Fig. 2Cc, Table 1) peptide or for the effects of
depolarizing PP in the presence of the NT (Fig. 3Cb,
Table 1) and the AID (Fig. 3Cc, Table 1) peptide. Given
these effects of CaV2.2 peptides on activation gating,
we next investigated the effects of CaV2.2 peptides
on Ca2+ current amplitude as a potential mechanism
underlying the inhibition of synaptic transmission
reported above. Following a conditioning prepulse to
+120mV to maximally relieve any endogenous G protein
modulation, the NT and the AID peptide both caused
a significant decrease in Ca2+ current density (Fig. 3D,
Table 2).
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Figure 3. Synthetic CaV2.2 peptides abolish prepulse facilitation of NA-induced inhibition of IBa
A, superimposed representative traces showing NA-induced inhibition of IBa (P1) and effects of a depolarizing
prepulse to +120 mV (P2) in control (a), and in the presence of NT peptide (1 mM) (b) and AID peptide (1 mM)
(c); test potential −10 mV; scale bars in Aa apply to each trace Aa–c. B, bar graphs summarizing facilitation ratio
(P2:P1) in the absence (white bars) and in the presence (grey bars) of NA (10 μM) in control (a), and in the presence
of NT peptide (1 mM) (b) and AID peptide (1 mM) (c); ∗P < 0.01 (paired Student’s t test). C, voltage dependence
of activation curves from tail current amplitude data in control (a), and in the presence of NT peptide (1 mM) (b)
and AID peptide (1 mM) (c). Filled circles represent tail current in the presence of 10 μM NA; open circles represent
tail current following a conditioning prepulse to +120 mV in the continued presence of NA. Control tail current
activation curve data (Ca) were described by one Boltzmann distribution; data recorded in the presence of the
NT (Cb) and AID (Cc) peptides ( ± PP) were well fitted only by two Boltzmann distributions (mean ± SEM values
derived from individual cells are shown in Table 1). D, bar graph summarizing inhibition of Ca2+ current density by
NT peptide (black bar) and AID peptide (grey bar) (mean ± SEM values derived from individual cells and conditions
are shown in Table 2); ∗P < 0.01 vs. control (Mann–Whitney U test).
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Table 2. Effects of CaV2.2 peptides on Ca2+ current density
Condition Current density (pA pF−1)
Control (n = 11) 17.6 ± 1.0
NT peptide (n = 11) 11.8 ± 0.4∗
AID peptide (n = 7) 11.3 ± 1.0∗
Mutant NT peptide (n = 6) 15.2 ± 0.9
Mutant AID peptide (n = 5) 7.8 ± 0.7∗
NT + AID peptide (n = 5) 17.5 ± 0.6
Current density was measured at least 15 min after formation
of whole-cell configuration following a conditioning prepulse
to +120 mV to maximally relieve any endogenous G protein
modulation (P2 at −10 mV, t from P1 = 20 ms). Peptides that
reduced EPSP amplitude in SCGN synapses (NT, AID and mutant
AID) all caused a significant decrease in current density. By
contrast, peptides that had no effect on EPSP amplitude in
SCG synapses (mutant NT) had no effect on current density.
∗P < 0.05 vs. control (Mann–WhitneyU test). ∗P < 0.05 vs. control;
Mann–Whitney U tests.
Overall, CaV2.2 peptides had an important inhibitory
effect on somaticCa2+ channels in isolated SCGNs causing
amodification in channel gating anda reduction in current
amplitude. These effects were also accompanied by a
reduced sensitivity to NA-induced G protein inhibition
and an inability to exhibit prepulse facilitation. Such
inhibitory peptide effects at presynaptic Ca2+ channels
are consistent with the reduction in synaptic transmission
and attenuation of G protein modulation demonstrated
in model SCGN synapses.
Effects of mutations to residues implicated
in Ca2+ channel function in NT and AID peptides
Previous studies have used site-directed mutagenesis
of full-length CaV2.2 subunits to implicate specific
amino acids within the NT and I–II loop as molecular
determinants of Ca2+ channel function (Dolphin, 2003;
De Waard et al. 2005; Tedford & Zamponi, 2006). With
these points in mind, we next examined the effect of
a CaV2.2[377–393] peptide containing an isoleucine to
leucine mutation in the third position within the QXXER
motif (I381L) (‘mutant AID peptide’). This isoleucine
residue has been reported to be a crucial determinant
for G protein modulation (Herlitze et al. 1997). In the
presence of the mutant AID peptide, activation curves
were asymmetrical about the midpoint and required the
sum of two Boltzmann distributions to be adequately
fitted (Fig. 4A), similar to the situation for the parent AID
peptide. The mutant AID peptide had an intermediate
effect on NA-induced inhibition of IBa (42.0± 5.0%,
n= 9; Fig. 4Ba and b). This degree of NA-mediated
inhibition was not significantly different either from
control or that seen with the unmodified AID peptide;
there was also no significant NA-induced shift inV 0.5 with
mutant AID (Table 1). As also seen with the unmodified
AID peptide, the mutant AID peptide abolished PPF
of NA-induced inhibition of IBa (P2:P1: 1.37± 0.15 at
−10mV, n= 7, P > 0.05; Fig. 4Ca and b) and negated
any PP-induced shift in voltage dependence of activation
(Fig. 4Cc, Table 1). Mutant AID peptide also caused a
significant reduction in Ca2+ current density (Fig. 4D,
Table 2). Consistent with these actions, the mutant AID
peptide caused a clear inhibition in cholinergic trans-
mission in model SCGN synapses (18± 3% decrease
in EPSP amplitude, n= 6, P < 0.05; Fig. 4E). Overall, a
CaV2.2 I381L mutation within the AID peptide sequence
did not abolish the inhibitory actions of the unmodified
AIDpeptide on synaptic transmission or onCa2+ channels
in isolated SCGNs.
We also investigated the effects of a CaV2.2[45–55]
peptide with two arginine residues replaced by alanine
(‘mutant NT peptide’). A full-length CaV2.2 R52A,R54A
channel is insensitive both toG proteinmodulation (Cantı´
et al. 1999) and to dominant-negative suppression by
the NT terminal (Page et al. 2010). By contrast to the
unmodified NT peptide described above, in the pre-
sence of the mutant NT peptide, tail current data were
best fitted by a single, major Boltzmann distribution
(Fig. 5A). The mutant NT peptide had negligible effects
on NA-induced inhibition, 10μM NA caused a robust
inhibition of IBa in isolated SCGNs (59.8± 5.5%, n= 9;
Fig. 5Ba and b), comparable to inhibition in controls
and significantly increased compared to the unmodified
NT peptide; NA also induced a significant shift in V 0.5
of ∼+7mV (Table 1). PPF of NA-induced inhibition
was still prominent with the mutant NT peptide (P2:P1:
1.70± 0.17 at −10mV, n= 8, P < 0.05; Fig. 5Ca and b).
PPF also caused a partial reversal of the NA-induced shift
in V 0.5 of ∼−4mV (Fig. 5Cc, Table 1); however, this was
outside the significance range (P = 0.16). Ca2+ current
density was unaffected by themutantNTpeptide (Fig. 5D,
Table 2). Inmodel SCGN synapses, themutantNTpeptide
had no effect on synaptic transmission (1.0± 3.5%
decrease in EPSP amplitude, n= 5; Fig. 5E). These data
implicate arginine residues within the CaV2.2[45–55] NT
peptide as being essential molecular determinants for
effects on Ca2+ channels and inhibition of synaptic trans-
mission in these systems.
Effects of AID and NT peptide co-application
Finally, we investigated the effects of co-application of the
NTpeptide and theAIDpeptide todetermine any additive,
antagonistic or supplemental effects in these systems. In
the jointpresenceofNTandAIDpeptides, tail currentdata
were best fitted by a single, major Boltzmann distribution
(Fig. 6A). Under joint NT/AID peptide application, 10μM
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Figure 4. A mutant AID peptide retains inhibitory effects on G protein modulation and synaptic
transmission
A, voltage dependence of activation curves from tail current amplitude data in the presence of the mutant AID
peptide (containing a CaV2.2 I381L mutation) (1 mM). Data recorded in the presence of the mutant AID peptide
were best fitted by two Boltzmann distributions (mean ± SEM values derived from individual cells are shown in
Table 1). Ba, representative traces showing 10 μM NA-induced inhibition of IBa in the presence of mutant AID
peptide (1 mM). Bb, bar graph summarizing percentage IBa inhibition by NA showing pooled data for controls
(white bar) and in the presence of mutant AID peptide (grey bar) and unmodified AID peptide (black bar);
∗P < 0.01 (Mann–Whitney U test). Ca, superimposed representative traces showing NA-induced inhibition of IBa
(P1) and effects of a prepulse (P2) in the presence of mutant AID peptide (1 mM). Cb, bar graph summarizing
facilitation ratio (P2:P1) for mutant AID peptide in the absence (white bars) and presence (grey bars) of NA
(10 μM). Cc, voltage dependence of activation curves for mutant AID peptide (1 mM) in the presence of NA
(10 μM, filled circles) and effect of conditioning prepulses in the continued presence of NA (open circles). In both
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NA caused a robust inhibition of IBa in isolated SCGNs
(54.2± 7.0%, n= 10; Fig. 6Ba and b), comparable to
inhibition in controls, and NA induced a significant
shift in V 0.5 of ∼+14mV (Table 1). PPF of NA-induced
inhibition was still prominent with NT/AID peptides
(P2:P1: 1.80± 0.30 at −10mV, n= 10, P < 0.05; Fig. 6Ca
and b); PPF also caused a reversal of the NA-induced
shift in V 0.5 of ∼−9mV (Fig. 6Cc, Table 1; P < 0.05).
Ca2+ current density was unaffected by co-application
of NT/AID peptides (Fig. 6D, Table 2). In model SCGN
synapses, combined injection of NT/AID peptides had
no effect on synaptic transmission (7.0± 5.7% decrease
in EPSP amplitude, n= 5; Fig. 6E). These data favour
a scenario whereby CaV2.2[45–55] and CaV2.2[377–393]
peptides act in an antagonistic manner for effects on Ca2+
channels and inhibition of synaptic transmission in these
systems.
Discussion
We demonstrate that synthetic Ca2+ channel peptides
based on the CaV2.2 NT or AID region inhibit synaptic
transmission and attenuate G protein modulation in
model SCGN synapses. We provide evidence that the
peptide mechanism of action in native SCGNs involves
effects on Ca2+ current amplitude and channel gating,
actions consistent with presynaptic inhibition of neuro-
transmitter release. Furthermore, co-application of NT
and AID peptides negated effects of individual peptides,
consistent with a scenario whereby the CaV2.2 NT[45–55]
and AID[377–393] sequences may interact.
Synthetic CaV2.2 peptides inhibit synaptic
transmission and attenuate G protein modulation
via an inhibitory effect on Ca2+ channels
A major advance here is the demonstration that
small 11mer CaV2.2 NT[45–55] and 17mer CaV2.2
AID[377–393] peptides act to functionally inhibit neuro-
transmission in SCGN synapses, an appropriate model
for studying presynaptic modulation of fast cholinergic
transmission (Mochida et al. 1994, 2003). Such effects are
accompanied by an attenuation of G protein modulation.
In agreement with our previous study describing a
Gβγ-mediated α2-adrenoceptor pathway in SCGNs
(Stephens & Mochida, 2005), we report that NA caused a
significant decrease in EPSP amplitude. The AID peptide
fully blocked NA inhibition, whilst the NT peptide caused
a significant reduction in NA effects. The latter data
were fully consistent with the level of inhibition seen for
individual peptides in the absence of NA and suggest a
maximum EPSP amplitude inhibition of ∼40% for this
pathway.
To investigate peptide mechanisms of action, we
made somatic recordings from isolated SCGNs. At
SCGN presynapses, transmitter release is supported pre-
dominantly by CaV2.2 channels (Mochida et al. 2003).
CaV expression is associated with heterogeneous CaVβ
and Gβγ subunit expression, both of which modulate
CaV activity (De Waard et al. 2005; Tedford & Zamponi,
2006); thus, we tested our peptides in the same native
SCG neuronal preparation as an appropriate model
of heterogeneous Ca2+ channels/auxiliary subunits at
the presynapse. NA inhibition of CaV2.2 channels
occurred via voltage-dependent pathways (and not
voltage-independent pathways, which are also prevalent
in SCGNs. Hille, 1994; Suh et al. 2010), as confirmed by
blockade of the prepulse relief of NA-induced inhibition
by PTX. Peptides that inhibited synaptic transmission also
caused a decrease in Ca2+ current amplitude (by contrast,
peptides lacking effects on synaptic transmission were
without effect on current amplitude). There was some
discrepancy here, in that the AID peptide had a stronger
inhibitory effect on EPSP amplitude than the NT peptide,
whilst a similar reduction in somatic Ca2+ current was
seen; this may reflect differences in peptide access to Ca2+
channels betweenwhole-cell recordings at the soma and in
SCGNmodel synapses, in which peptides are injected into
the presynaptic partner and must diffuse into presynaptic
terminals in order to act (Mochida et al. 1996). Here, we
cannot fully rule out that NT and AID peptide are trans-
ported differentially to the presynapse. Overall, reductions
in Ca2+ current amplitude favour a major mechanism
whereby NT and AID peptides interact with presynaptic
Ca2+ channels in SCGNsynapses, such that fewer channels
are activated in response to depolarizing action potentials
and, consequently, less acetylcholine is released.
NT and AID peptides were found to have complex
inhibitory effects on the voltage dependence of activation.
Control activation was best described by a single
Boltzmann component; by contrast, in the presence of
NT or AID peptide, a double Boltzmann fit was required.
Dual Boltzmann distributions have been correlated with a
cases, tail current activation curve data recorded in the presence of the mutant AID peptide were well fitted only by
two Boltzmann distributions (mean ± SEM values derived from individual cells are shown in Table 1). D, bar graph
summarizing inhibition of Ca2+ current density by mutant AID peptide (black bar) (mean ± SEM values derived
from individual cells and conditions are shown in Table 2); ∗P < 0.01 vs. control (Mann–Whitney U test). E, effect
of mutant AID peptide (1 mM in the pipette) on EPSP amplitude in model SCGN synapses. Note that CaV2.2 I381L
mutant peptide retained the inhibitory effects seen for unmodified AID peptide.
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Figure 5. A mutant NT peptide lacks inhibitory effects on G protein modulation and synaptic
transmission
A, voltage dependence of activation curves from tail current amplitude data in the presence of the mutant NT
peptide (containing CaV2.2 R52A,R54A mutations) (1 mM). Mutant NT peptide tail current activation curve data
were best described by a single Boltzmann distribution (mean ± SEM values derived from individual cells are shown
in Table 1). Ba, representative traces showing 10 μM NA-induced inhibition of IBa in the presence of mutant NT
peptide (1 mM). Bb, bar graph summarizing percentage IBa inhibition by NA showing pooled data for controls
(white bar) and in the presence of mutant NT peptide (grey bar) and unmodified NT peptide (black bar); ∗P < 0.01
vs. control, †P < 0.01 vs. mutant NT peptide (Mann–Whitney U tests). Ca, superimposed representative traces
showing NA-induced inhibition of IBa (P1) and effects of a prepulse (P2) in the presence of mutant NT peptide
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lower, Gβγ-unbound ‘willing’ and a higher, Gβγ-bound
‘reluctant’ activation state (Bean, 1989; Ikeda, 1991).
Moreover, Agler et al. (2003) have developed a compound
gating model to describe G protein inhibition whereby, in
the absence of Gβγ, channels are willing to open following
transition through five closed states (C1–C5); the binding
of Gβγ specifies reluctant opening by promoting entry
into five corresponding deep closed states (C1∗–C5∗).
Here, NT and AID peptides may promote transitions
into reluctant C1∗–C5∗ states, as substantiated by the
switch from a single, willing population to one also
containing a second, reluctant component. If we apply
dual Boltzmann fits to the control data, significantly more
channels are described by the lower ‘willing’ component
(85± 2%), and significantly fewer channels are described
by the higher ‘reluctant’ component (13± 2%) than
the corresponding components with either NT or AID
peptide (each P < 0.05, Mann–Whitney U tests); such
differences are consistent with more channels being
‘reluctant’ to open in the presence of these inhibitory
peptides. Overall, our functional data demonstrate that
the CaV2.2 peptide-induced changes to activation gating
were accompanied by an reduction in Ca2+ current
amplitude; such actions at presynaptic Ca2+ channels are
consistent with inhibition of synaptic transmission. The
demonstration that CaV2.2 peptides alone inhibit synaptic
transmission is consistent with an action independent
from previously reported effects for AID-based peptides
on G protein modulation (Herlitze et al. 1997; Zamponi
et al. 1997). Previous studies have shown that the
co-expression of the NT[1–95] domain suppresses CaV2.2
Ca2+ current (Raghib et al. 2001; Page et al. 2004, 2010;
Agler et al. 2005). Here, we extend these reports to
show that a synthetic peptide minimally consisting of the
CaV2.2[45–55] N-terminal can modulate Ca2+ channels
and inhibit synaptic transmission.
Accompanying their effects on Ca2+ current amplitude
and channel gating, NT and AID peptides also disrupted
hallmark properties of GPCR-mediated inhibition in
SCGNs (Stephens & Mochida, 2005). Thus, NT and
AID peptides attenuated (i) NA-induced inhibition of
EPSP amplitude in SCGN synapses, (ii) NA-induced
inhibition of IBa amplitude, (iii) NA-induced shift in
voltage dependence of activation, and (iv) prepulse relief
of NA-induced inhibition in isolated SCGNs. Modulation
of G protein inhibition could be explained by peptides
binding and chelating free Gβγ (Zamponi et al. 1997),
or by peptides interacting with the Ca2+ channel itself
(Agler et al. 2005).Here, several observations argue against
sequestration of Gβγ as an exclusive mechanism. Thus,
in the presence of peptides: (i) synaptic transmission
in SCGN synapses was inhibited, a simple chelation
of Gβγ subunits would be expected to remove tonic
inhibition; (ii) there were no clear changes in endogenous
G protein modulation (including basal facilitation ratio);
(iii) voltage dependence of activation was best described
by a dual, and not a single, component; for the latter, Gβγ
sequestration by peptides would be expected to favour
dominance by a single, uninhibited channel population;
(iv) there was no decrease in G protein reinhibition
kinetics following a depolarizing prepulse (Supplemental
Fig. 2).
Overall, our data favour a scenario in which inhibitory
effects of the NT and the AID peptide are due to inter-
action with Ca2+ channels; thus, these peptides may
bind the CaV2.2 subunit to cause inhibition. Experiments
with co-application of NT and AID peptides showed
an antagonistic effect on synaptic transmission, Ca2+
channel action and G protein modulation, such that
the two peptides may bind each other to negate the
effects of the parent peptide; such data strengthen the
hypothesis of a physical interaction between CaV2.2
NT[45–55] and AID[377–393] sequences. We propose
that peptide/CaV2.2 channel interactions (whether at
a NT-I–II loop or alternative binding site) result in
changes to gating and reduced current amplitude, and
a consequent inhibition of synaptic transmission. Under
these conditions, the peptide/Ca2+ channel complex is
unresponsive to G protein modulation, as reported by
other groups (Herlitze et al. 1997; Zamponi et al. 1997;
Agler et al. 2005; Page et al. 2010). Agler et al. (2005) have
demonstrated binding between the NT[1–95] domain
and the first third of the I–II loop (CaV2.2[357–393]) in
yeast two-hybrid assays and proposed that this promotes
‘constitutively reluctant’ Ca2+ channel gating. By contrast,
no interaction between NT[1–95] and the I–II loop were
(1 mM). Cb, bar graph summarizing facilitation ratio (P2:P1) for mutant NT peptide in the absence (white bars) and
presence (grey bars) of NA (10 μM); ∗P < 0.01 (paired Student’s t test). Cc, voltage dependence of activation curves
for mutant NT peptide (1 mM) in the presence of NA (10 μM, filled circles) and effect of conditioning prepulses
in the continued presence of NA (open circles). In both cases, tail current activation curve data recorded in the
presence of the mutant NT peptide were well fitted by a single Boltzmann distribution (mean ± SEM values derived
from individual cells are shown in Table 1). D, bar graph summarizing effect of mutant NT peptide (black bar)
on Ca2+ current density (mean ± SEM values derived from individual cells and conditions are shown in Table 2).
E, effect of mutant NT peptide (1 mM in the pipette) on EPSP amplitude in model SCGN synapses. Note that
CaV2.2 R52A,R54A mutant peptide had no inhibitory effects on G protein modulation or synaptic transmission,
by contrast to effects seen with unmodified NT peptide.
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Figure 6. Co-application of NT and AID peptides negates inhibitory effects on G protein modulation
and synaptic transmission
A, voltage dependence of activation curves from tail current amplitude data for combined application of the NT
and the AID peptide (both 1 mM). NT/AID peptide tail current activation curve data were best described by a single
Boltzmann distribution (mean ± SEM values derived from individual cells are shown in Table 1). Ba, representative
traces showing 10 μM NA-induced inhibition of IBa in the presence of NT/AID peptide (both 1 mM). Bb, bar graph
summarizing percentage IBa inhibition by NA showing pooled data for controls (white bar) and in the presence
of NT/AID peptide (grey bar). Ca, superimposed representative traces showing NA-induced inhibition of IBa (P1)
and effects of a prepulse (P2) in the presence of NT/AID peptide (1 mM). Cb, bar graph summarizing facilitation
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found in similar assays (Page et al. 2010), who instead
proposed that the NT may interact with a distant binding
pocket to cause functional effects. Additionally, Page
et al. (2004) have proposed that expression of the NT
causes activation of the endoplasmic reticulum resident
RNA-dependent kinase, PERK, to suppress Ca2+ channel
translation; however, such amechanism is likely tobemore
longer term than the acute effects reported in the pre-
sent study. Importantly, previously studies using CaV2.2
peptides have been performed exclusively in recombinant
cells; here, we extend studies to native neurones.
Mutations to synthetic CaV2.2 peptides reveal an
important role for the NT in Ca2+ channel regulation
As discussed above, we propose that the CaV2.2 peptides
used here interact with the Ca2+ channel to affect
function. Therefore, mutations to residues shown to
be determinants of Ca2+ channel function may affect
actions of NT or AID peptides. In this regard, NT
residues arginine 52 and arginine 54 are important
molecular determinants for G protein regulation (Page
et al. 1998; Stephens et al. 1998b; Cantı´ et al. 1999) and for
dominant-negative suppression of CaV2 channels (Page
et al. 2010). Most significantly here, when the NT peptide
was modified to contain equivalent CaV2.2 R52A,R54A
mutations, the resultant peptide was unable to inhibit
synaptic transmission and lacked the inhibitory effects
on Ca2+ channels seen with the unmodified NT peptide.
With regard to G protein modulation, Agler et al. (2005)
have proposed that the inhibitory interaction between NT
and AID is dependent on the presence of Gβγ; our data
lend support to this concept, as mutations that prevent
G protein modulation also ablate the inhibitory effects of
the NT peptide on synaptic transmission and G protein
modulation.
By contrast, our data do not provide support a role
for isoleucine 381 as a crucial determinant for the
Ca2+ channel functions investigated here. However, it is
important to point out that isolated peptides lack the
tertiary structure of the channel in the native environment
and that mutation of isoleucine to leucine within the
proposed QXXER binding motif has been shown to affect
G protein modulation in the full-length channel (Herlitze
et al. 1997). Moreover, we cannot exclude the involvement
of alternative residues within the AID region in Ca2+
channel functions such as G protein modulation (De
Waard et al. 1997; Zamponi et al. 1997, Tedford et al.
2010).
It also remains to be fully determined how peptide
effects on other elements may also contribute. For
example, it is possible that disrupting CaV2(α1)/CaVβ
interactions, crucial to Ca2+ channel function (Dolphin,
2003), may also contribute to effects reported here.
CaVβ binds the AID region (Richards et al. 2004)
and NT[44–55] contributes to CaVβ modulation of
inactivation (Stephens et al. 2000). The CaVβ subunit has
been proposed to be indispensable for Gβγ inhibition
(Meir et al. 2000; Herlitze et al. 2001; Hu¨mmer et al.
2003). CaVβ has been shown to modulate the IS6-AID
linker region responsible for α1 subunit activation gating
(Opatowsky et al. 2004; Van Petegem et al. 2004) and
disruption of this region prevents Gβγ inhibition (Zhang
et al. 2008). Interestingly, a CaV2.2[353–371] peptide,
encompassing the IS6-AID linker, was shown to block
G protein modulation (Zamponi et al. 1997). Overall,
our data add to accumulating evidence suggesting that
modulation of Ca2+ channels is dependent on interaction
between multiple intracellular elements of presynaptic
CaV2 channels; our data support a dominant role for
the NT and, in particular R52 and R54, as important
determinants of Ca2+ channel function.
Potential therapeutic significance
CaV2.2 channels are key determinants of hyperexcitability
disorders associated with increased or ectopic neuronal
firing, for example, in neuropathic pain (Chaplan et al.
1994; Matthews & Dickenson, 2001; Yang & Stephens,
2009). CaV2.2 channels are therapeutically targeted by
GPCR ligands such as opioids, but remain a significant
focus for novel drug development (Altier & Zamponi,
2004). The search for improved analgesics generated
the CaV2.2 blocker ziconotide; although providing a
useful proof-of-concept, this compound has a narrow
ratio (P2:P1) for NT/AID peptide in the absence (white bars) and presence (grey bars) of NA (10 μM); ∗P < 0.01
(paired Student’s t test). Cc, voltage dependence of activation curves for NT/AID peptide (1 mM) in the presence
of NA (10 μM, filled circles) and effect of conditioning prepulses in the continued presence of NA (open circles).
In both cases, tail current activation curve data recorded in the presence of NT/AID peptide were well fitted by
a single Boltzmann distribution (mean ± SEM values derived from individual cells are shown in Table 1). D, bar
graph summarizing effect of NT/AID peptide (black bar) on Ca2+ current density (mean ± SEM values derived
from individual cells and conditions are shown in Table 2). E, effect of NT/AID peptide (1 mM in the pipette)
on EPSP amplitude in model SCGN synapses. Note that co-application of NT/AID peptide had no inhibitory
effects on G protein modulation or synaptic transmission, by contrast to effects seen with unmodified parent
peptides.
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therapeutic window (Williams et al. 2008). We show
that small, synthetic CaV2.2 peptides can inhibit trans-
mitter release; knowledge of mechanisms of presynaptic
inhibition may serve as a starting point to develop new
therapeutic agents.
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